Author:
Rhodes Anthony,Jasani Bharat,Anderson Elizabeth,Dodson Andrew R.,Balaton André J.
Publisher
Oxford University Press (OUP)
Reference30 articles.
1. Pegram MD, Lipton A, Hayes DF, et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185 monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol. 1998;16:2659-2671.
2. Slamon D, Leyland-Jones B, Shak S, et al. Addition of Herceptin (humanized anti-Her2 antibody) to first line chemotherapy for Her2 overexpressing metastatic breast cancer (Her2+/MBC) markedly increases anticancer activity: a randomised multinational controlled phase III trial [abstract]. Proc Am Soc Clin Oncol. 1998;17:98A. Abstract 377.
3. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-over-expressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999;17:2639-2648.
4. Allred DC, Swanson PE. Testing for erbB-2 by immuno-histochemistry in breast cancer. Am J Clin Pathol. 2000;113:171-175.
5. Clark GM. Prognostic and predictive factors. In: Harris JR, Lippman ME, Morrow M, et al, eds. Diseases of the Breast. Philadelphia, PA: Lippincott-Raven; 1996:461-485.
Cited by
110 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献